Loading...
NPI 1790320380 · Ann Arbor, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Strata Oncology, Inc. is a clinical medical laboratory provider located in Ann Arbor, Michigan. This profile covers 3 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Strata Oncology, Inc. |
| Address | 8170 Jackson Rd Ste A |
| City | Ann Arbor |
| State | MI |
| ZIP | 48103 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 7, 2019 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.5M |
| Medicaid | $30.6K |
STRATA ONCOLOGY, INC. presents as a clinical molecular laboratory focused on tumor profiling: its Medicare mix is dominated by molecular pathology and a Proprietary Laboratory Analyses (PLA) next‑generation sequencing test. The presence of 81479 (molecular pathology unspecified) and PLA code 0391U (Strata Select NGS for 437 genes) as the top Medicare revenue drivers, plus a small volume of 88360 (single antibody stain interpretation), indicates the operation centers on NGS-based tumor profiling with limited traditional histopathology billing.
Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes account for 100.0% of the provider's Medicare revenue, driven by 81479 at $814.4K (55.3% of Medicare revenue) and 0391U at $648.3K (44.1% of Medicare revenue), while 88360 contributes $8.8K (0.6%). This concentration shows that two molecular pathology codes effectively underlie the entirety of the $1.5M Medicare billing profile.
Medicaid activity is minimal and tightly concentrated: total Medicaid revenue is $30.6K and 81479 represents 100.0% of that Medicaid revenue, with 140 claims and $219 avg paid/claim. This means the provider has a very limited Medicaid footprint that mirrors its Medicare molecular pathology billing rather than a diversified state-payer service mix.
Payer mix is Medicare-dominant: Medicare revenue ($1.5M) dwarfs Medicaid revenue ($30.6K), indicating the provider operates predominantly in the Medicare market rather than as a dual-payer-balanced lab. Analysts should treat Medicaid exposure as negligible relative to the Medicare business when modeling revenue sensitivity or payer contracting risk.
Competitive standing for the proprietary test is unique: 0391U ranks #1 of 1 providers nationally with no national peer volume comparison available, reflecting that this PLA is reported only for Strata Select and therefore isn't benchmarkable against other labs. Given that 0391U accounts for $648.3K (44.1% of Medicare revenue), the provider’s commercialized PLA is a material, non-comparable revenue source on Medicare.
For the generic molecular and pathology services, national rankings place the provider in a middle-to-typical position: 81479 ranks #34 of 80 nationally (58th percentile; typical, unremarkable volume for this code) and 88360 ranks #1539 of 5330 nationally (71th percentile; typical, unremarkable volume for this code). These ranks suggest the provider is not a dominant national volume leader for commonly reported molecular pathology or single-stain interpretation services, despite its proprietary test significance.
State-level Medicaid positioning for 81479 is also modest: 81479 ranks #3 of 5 providers in-state (50th percentile; typical, unremarkable volume for this code), reinforcing that Strata’s Medicaid presence is limited and in line with typical statewide billing patterns rather than concentrated market dominance. This underscores a business model concentrated on Medicare molecular testing rather than broad Medicaid services.
Tenure and commercialization timeline: the NPI was enumerated on 2019-11-07 (~7 years ago), and within that period the provider has developed a distinct revenue profile including a proprietary PLA product and substantial Medicare billing totaling $1.5M. The combination of a short-to-moderate market tenure and a high-revenue proprietary code suggests rapid product commercialization within the molecular oncology testing niche.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 270 | $2,990 | $814.4K |
| 0391U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0391U only for… | 190 | $3,430 | $648.3K |
| 88360 | The lab analyst applies a single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist, evaluates the… | 100 | $90 | $8.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 140 | $220 | $30.7K |
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 3 | 10 | 140 | $10 | $53K |
Other providers in the same ZIP code as Strata Oncology, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Adult Learning Systems-lower Michigan Inc | MI | Mental Illness Community Based Residential Treatment Facility | $0 | $39.1M |
| Iha Health Services Corporation | MI | Pediatrics Physician | $0 | $9.1M |
| Crc Recovery Inc | MI | Methadone Clinic | $90.6K | $6.3M |
| Allison Stoecker | MI | MOHS-Micrographic Surgery Physician | $514.4K | $0 |
| John Murray | MI | Diagnostic Radiology Physician | $153.2K | $0 |
| Suzanne Jones | MI | Surgery Physician | $122.8K | $0 |
| Mala Young | MI | Physical Medicine & Rehabilitation Physician | $120.3K | $0 |
| Malcolm Sickels | MI | Family Medicine Physician | $114K | $0 |
| Woodward Detroit Cvs, L.L.C. | MI | Pharmacy | $108.6K | $0 |
| Elisa Ostafin | MI | Internal Medicine Physician | $106.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.